Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 1

Status

Completed 9Unknown 4Terminated 3Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 10Neoplasms 6Prostatic Neoplasms 5Anxiety Disorders 5Leukemia 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms, Plasma Cell 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma 3Fatigue 3Depression 3Colorectal Neoplasms 3Rectal Neoplasms 2Primary Myelofibrosis 2Hodgkin Disease 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Anus Neoplasms 2cyclopia sequence 1Vulvar Neoplasms 1Vomiting 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Surveys and Questionnaires × Clear all
NCT04716153 2026-01-20

RE-NEZ-SENS

University Hospital, Montpellier

Phase NA Terminated
5 enrolled
LymphoidPlasma cell

Anosmia, Lymphoma, Multiple Myeloma

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

NCT01927718 2019-04-29

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 5 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡